/
Our mission is to build a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. We have developed, licensed, and acquired a portfolio of meaningfully differentiated products for use in the treatment of attention deficit hyperactivity disorder ( ADHD ) and moderate to severe pain.
Margins and capital returns are both well above average: 23.01% operating margin, ROIC at 29.44%. Consistent with durable pricing power, though that alone doesn't make it a buy.
Revenue grew 23.6%, still solid. Margins contracted 3.9pp, which offsets some of the top-line progress.
Operating margin contracted 3.9pp YoY, cost discipline may be slipping.
Profitability & Returns
Revenue (TTM)
$796M
▲ +23.6% YoY
Net Income (TTM)
$75M
▼ -9.1% YoY
Op. Margin
23.81%
▼ -3.9pp YoY
ROIC
29.83%
▼ -0.5pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$330M
▲ +61.1% YoY
Op. Cash Flow (TTM)
$331M
▲ +60.7% YoY
Net Debt
-$178M
Net Cash Position
Cash & Equiv.
$422M
5Y CAGR: +20.3%
5Y CAGR: +30.0%
Continue Research